Maxwell Biosciences Announces Closing of $20M Financing Round
Austin, Texas--(Newsfile Corp. - August 7, 2025) - Maxwell Biosciences, a global health technology company pioneering a new category of immune-inspired small molecules called Claromers™, today announced the closing of its $20 million financing round. The funds will support Maxwell's upcoming FDA clinical trials and advance AI-driven R&D. The funds will also expand commercialization in multiple other industries in which nontoxic antiseptics are highly valued, such as cosmetics, clean
Biotechnology, Pharmaceuticals
2025-08-07 9:30 AM EDT | Maxwell Biosciences, Inc.
OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
66.6% of OST-HER2 treated patients achieved 2-year overall survival compared with 40% in the historical control group (p = 0.0046) FDA issues Biologics Licensing Application (BLA) number for OST-HER2 in preparation for anticipated BLA filing for the prevention or delay of recurrent, fully resected, pulmonary metastatic osteosarcoma following August 27, 2025 End of Phase 2 Meeting Company responds to FDA correspondences see
2025-08-07 9:00 AM EDT | OS Therapies
TempraMed Partners with the Diabetes Education & Camping Association of the USA (DECA), Supporting Safe Insulin Storage for Children at Diabetes Camps Across the United States
Sammamish, Washington--(Newsfile Corp. - August 7, 2025) - TempraMed Ltd. ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is proud to announce a new partnership with the Diabetes Education & Camping Association (DECA) by providing VIVI Cap devices to diabetes camps across the United States. As part of this partnership, TempraMed is providing these critical temperature-sensitive s
Technology, Biotechnology, Pharmaceuticals, Health
2025-08-07 7:00 AM EDT | TempraMed Technologies Ltd
Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Encinitas, California--(Newsfile Corp. - August 7, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that its President and CEO, Brian M. Strem, Ph.D., will showcase the Company's pipeline of therapies targeting inherited and inflammatory retinal diseases at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. Presentation Details
Biotechnology, Pharmaceuticals
2025-08-07 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it held a successful Scientific Advice Meeting
2025-08-07 6:00 AM EDT | OS Therapies
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx™ over placebo. Reduction in ECV was associated with improvements across multiple pre-specified cardiac magnetic resonance imaging (CMR) endpoints, including a significant reduction in LV mass. The ARCHER trial results provide compelling clinical proof of conce
Biotechnology, Cannabis, Health, Cannabis Manufacturer
2025-08-06 7:27 AM EDT | Cardiol Therapeutics Inc.
Medexus Schedules First Fiscal Quarter 2026 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - August 5, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, August 13, 2025 to discuss Medexus's results for its first fiscal quarter ended June 30, 2025. Medexus expects to file its financial statements and MD&A after markets close on August 12, 2025. To participate in the call, please dial the following numbers:
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-08-05 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Telo Genomics to Present at the OTCQB Venture Virtual Investor Conference
Toronto, Ontario--(Newsfile Corp. - August 5, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that it will present at the OTCQB Venture Virtual Investor Conference on August 7th, 2025. This will be a live, interactive online event where investors are invited to ask the company questions in re
2025-08-05 4:10 PM EDT | Telo Genomics Corp.
CellCentric to Participate in Upcoming Investor Conferences
United Kingdom and Boston, Massachusetts--(Newsfile Corp. - August 5, 2025) - CellCentric, a privately held biotechnology company developing inobrodib, a first-in-class p300/CBP inhibitor for multiple myeloma, today announced that members of its senior management team will participate in several upcoming investor conferences. These events provide an opportunity to engage with the investment community and highlight the company's clinical progress with inobrodib, which wi
2025-08-05 9:28 AM EDT | CellCentric, Inc
BioMark Diagnostics Announces Expansion of Its Specialty Laboratory Services in Quebec to Accommodate Increased Demand from International Partnerships
Vancouver, British Columbia--(Newsfile Corp. - August 5, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, announces today the completion of a strategic laboratory equipment leasing agreement, substantially doubling BioMark's testing capacity and positioning the Company for the imminent commercial launch of its lung cancer assay. This critical advancement in its operational capabi
Technology, Biotechnology, Healthcare and Hospitals
2025-08-05 8:30 AM EDT | BioMark Diagnostics, Inc.
AquaBounty Technologies Announces Second Quarter 2025 Financial Results
Harvard, Massachusetts--(Newsfile Corp. - August 5, 2025) - AquaBounty Technologies, Inc. (NASDAQ: AQB) ("AquaBounty" or the "Company"), a land-based aquaculture company utilizing technology to enhance productivity and sustainability, today announced the Company's financial results for the second quarter and six months ended June 30, 2025. Second Quarter 2025 Highlights Net loss for the quarter ended June 30, 2025 was $3.4 million comp
Agriculture, Biotechnology, Food / Beverages
2025-08-05 8:00 AM EDT | AquaBounty Technologies, Inc.
GRAFAPEX (treosulfan) for Injection Receives CMS Approval of New Technology Add-On Payment (NTAP) for Eligible Cases in CMS's Fiscal Year 2026
Ontario and Chicago, Illinois--(Newsfile Corp. - August 5, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that the US Centers for Medicare & Medicaid Services (CMS) has approved New Technology Add-On Payment (NTAP) reimbursement for eligible cases involving the use of GRAFAPEX™ (treosulfan) for Injection for CMS's fiscal year 2026, which runs from October 1, 2025 to September 30, 2026.* The NTAP program is designed to provide temporar
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-08-05 7:00 AM EDT | Medexus Pharmaceuticals Inc.
BioHarvest Sciences to Host Second Quarter 2025 Earnings Call on August 11 at 8:00 a.m. Eastern Time
Rehovot, Israel--(Newsfile Corp. - August 4, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the second quarter ended June 30, 2025 before market open on Monday, August 11, 2025. Management will host an investor conference call and webcast at 8:00 a
Biotechnology, Pharmaceuticals, Health
2025-08-04 8:30 AM EDT | BioHarvest Sciences Inc.
Medicus Pharma Ltd. Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies Inc. to Develop Thermostable Infectious Disease Vaccines
Philadelphia, Pennsylvania--(Newsfile Corp. - August 4, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus") and Helix Nanotechnologies Inc. ("HelixNano"), a Boston-based biotech company focused on developing an advanced mRNA platform to create vaccines and therapies to augment the immune system's power to fight disease, announced today that they have entered into a non-binding memorandum of understanding (the "MoU") in respect of their shared mutual interest in the dev
Banking / Financial Services, Biotechnology, Investment Banking, Health
2025-08-04 7:30 AM EDT | Medicus Pharma Ltd.
Hemostemix Increases Previously Closed Private Placement to $3,000,000
Calgary, Alberta--(Newsfile Corp. - July 31, 2025) - Further to its press release dated July 24, 2025, Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") wishes to provide an update regarding its previously closed non-brokered private placement (the "Offering"). The Company confirms that, following the receipt of additional subscriptions not included in the original Offering which closed on July 23, 2025, the size of the Offering
Biotechnology, Pharmaceuticals, Health
2025-07-31 5:53 PM EDT | Hemostemix Inc.
Cells: Hemostemix ACP-01 Provides the Scientific Basis for Improving the Longevity and Signal Uptake of Brain Computer Implants
Calgary, Alberta--(Newsfile Corp. - July 31, 2025) - Hemostemix (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is excited to highlight a groundbreaking research article published in Cells on June 29, 2025, by Fraser C. Henderson Sr. and Ms. Kelly Tuchman, exploring how a combination of the patient's own ACP-01 and NCP-01 (autologous blood-derived cell precursors) may s
Biotechnology, Pharmaceuticals, Health
2025-07-31 2:49 PM EDT | Hemostemix Inc.
Envoy Medical Reports on Second Quarter 2025 Results
White Bear Lake, Minnesota--(Newsfile Corp. - July 31, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the second quarter ended June 30, 2025, as well as other subsequent events. Financial and Corporate Highlights for Second Quarter and to date: Strong momentum continu
Biotechnology, Healthcare and Hospitals
2025-07-31 8:00 AM EDT | Envoy Medical, Inc.
PharmaDrug Inc.: Correction to News Release Dated July 30, 2025
Toronto, Ontario--(Newsfile Corp. - July 30, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), announces that the original news release captioned "PharmaDrug Signs LOI to Acquire Equity Interest in Canurta Inc." published on July 30, 2025 referred, incorrectly, to the number of common shares of PharmaDrug to be issued in the second tranche of the proposed transaction and the total number of shares to be issued pursuant to both tranches. The
Biotechnology, Cannabis, Psychedelics, Cannabis Manufacturer
2025-07-30 11:37 AM EDT | PharmaDrug Inc.
BioMark Diagnostics Highlights Fiscal Year 2025 Achievements and Sets Bold Strategic Milestones for 2025 - 2026
Vancouver, British Columbia--(Newsfile Corp. - July 30, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy tests for early cancer detection, today announced a summary of its fiscal year 2025 highlights and key milestones for 2025 - 2026. The Company's annual financial filings are available on the SEDAR+ website at www.sedarplus.ca and o
Technology, Biotechnology, Healthcare and Hospitals
2025-07-30 8:30 AM EDT | BioMark Diagnostics, Inc.
PharmaDrug Signs LOI to Acquire Equity Interest in Canurta Inc.
Toronto, Ontario--(Newsfile Corp. - July 30, 2025) - PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines is announcing that it has entered into a non-binding Letter of Intent ("LOI") on July 23rd, 2025 to acquire up to a 40% equity interest in Canurta Limited Partnership ("Canurta"), the parent entity of Canurta In
Biotechnology, Cannabis, Psychedelics, Cannabis Manufacturer
2025-07-30 7:30 AM EDT | PharmaDrug Inc.